Immunotherapy retreatment with serplulimab vs. chemotherapy in extensive-stage advanced small cell lung cancer.

Oncol Lett · 2026 · PMC13177285 · PMID 42145910

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significanceP>0.05actually significant

For other subgroups, including patients aged >65 years, those with ECOG PS 0 or 1, and those with first-line radiotherapy, serplulimab showed an improved PFS, although these results did not reach statistical significance compared with the chemotherapy group (all P>0.05).

also in 111,027 other papers

showed a trendno p-value reported

In the remaining subgroups, serplulimab showed a trend of OS benefit, but the differences compared with the chemotherapy group were not statistically significant (all P>0.05).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.